Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of AK112 + AK117 with or without chemotherapy in advanced malignant tumors
CTR20212989Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Jan 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab, ligufalimab in Non-hematologic malignancy, ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), hepatocellular carcinoma (HCC), sponsored by Akeso, Inc.. Started Jan 2022; status: completed.
02
Drugs
ivonescimabligufalimab
03
Conditions
Non-hematologic malignancyovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20212989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212989.